In this task, you're given a paragraph and title from the research paper. Your task is to classify whether the given title is suitable or not for the research paper based on the given paragraph. Return "True" if title is proper according to paragraph else "False".

Ex Input:
Paragraph: Bernard, S., Bottreau, E., Aynaud, J.M., Have, P. and Szymansky, J., 1989. Natural infection with the porcine respiratory coronavirus induces protective lactogenic immunity against transmissible gastroenteritis. Vet. Microbiol., 21: 1-8. Our objective was to evaluate the level of passive protection against transmissible gastroenteritis (TGE) among 57 newborn piglets nursing from seven seropositive sows previously naturally infected with porcine respiratory coronavirus (PRCV). After challenge exposure we observed mortality rates of 44% for litters of seven PRCV-infected sows, 40% for litters of four sows orally immunized with the attenuated TGEV strain Nouzilly, and 91% for litters of seven seronegative susceptible sows. A blocking ELISA with two appropriate monoclonal antibodies distinguished serological responses of PRCV-infected sows from those of TGEV-immunized sows. The results suggest that natural infection of the sow with PRCV may induce a degree of protective lactogenic immunity against TGE. 
 Title: Natural Infection with the Porcine Respiratory Coronavirus Induces Protective Lactogenic Immunity against Transmissible Gastroenteritis

Ex Output:
True


Ex Input:
Paragraph: Background 3 In silico bacterial, viral, and human truth datasets were generated to evaluate available metagenomics 4 algorithms. Sequenced datasets include background organisms, creating ambiguity in the true 5 source organism for each read. Bacterial and viral datasets were created with even and staggered 6 coverage to evaluate organism identification, read mapping, and gene identification capabilities of 7 available algorithms. These truth datasets are provided as a resource for the development and 8 refinement of metagenomic algorithms. Algorithm performance on these truth datasets can inform 9 decision makers on strengths and weaknesses of available algorithms and how the results may be best 10 leveraged for bacterial and viral organism identification and characterization. 11 12 Source organisms were selected to mirror communities described in the Human Microbiome Project as 13 well as the emerging pathogens listed by the National Institute of Allergy and Infectious Diseases. The 14 six in silico datasets were used to evaluate the performance of six leading metagenomics algorithms: 15 MetaScope, Kraken, LMAT, MetaPhlAn, MetaCV, and MetaPhyler. 16 Results Algorithms were evaluated on runtime, true positive organisms identified to the genus and species 19 levels, false positive organisms identified to genus and species level, read mapping, relative abundance 20 estimation, and gene calling. No algorithm out performed the others in all categories, and the 21 algorithm or algorithms of choice strongly depends on analysis goals. MetaPhlAn excels for bacteria 22 and LMAT for viruses. The algorithms were ranked by overall performance using a normalized 23 weighted sum of the above metrics, and MetaScope emerged as the overall winner, followed by Kraken 24 and LMAT. 25 Conclusions 27 Simulated FASTQ datasets with well--characterized truth data about microbial community composition 28 reveal numerous insights about the relative strengths and weaknesses of the metagenomics algorithms 29 evaluated. The simulated datasets are available to download from the Sequence Read Archive 30 (SRP062063). 31 32 
 Title: Evaluating performance of metagenomic characterization algorithms using in silico datasets generated with FASTQSim

Ex Output:
False


Ex Input:
Paragraph: currently under evaluation as a human immunodeficiency virus (HIV)-1 vaccine vector. The most compelling reasons to develop rVSV as a vaccine vector include a very low seroprevalence in humans, the ability to infect and robustly express foreign antigens in a broad range of cells, and vigorous growth in continuous cell lines used for vaccine manufacture. Numerous preclinical studies with rVSV vectors expressing antigens from a variety of human pathogens have demonstrated the versatility, flexibility, and potential efficacy of the rVSV vaccine platform. When administered to nonhuman primates (NHPs), rVSV vectors expressing HIV-1 Gag and Env elicited robust HIV-1specific cellular and humoral immune responses, and animals immunized with rVSV vectors expressing simian immunodeficiency virus (SIV) Gag and HIV Env were protected from AIDS after challenge with a pathogenic SIV/HIV recombinant. However, results from an exploratory neurovirulence study in NHPs indicated that these prototypic rVSV vectors might not be adequately attenuated for widespread use in human populations. To address this safety concern, a variety of different attenuation strategies, designed to produce a range of further attenuated rVSV vectors, are currently under investigation. Additional modifications of further attenuated rVSV vectors to upregulate expression of HIV-1 antigens and coexpress molecular adjuvants are also being developed in an effort to balance immunogenicity and attenuation. 
 Title: Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector

Ex Output:

False